Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC
New Delhi: The Subject Expert Committee (SEC) under the Reproductive division of the Central Drugs Standard Control Organization (CDSCO) has recommended the grant of permission for the manufacturing and marketing of a Fixed Dose Combination (FDC) of Relugolix 40 mg, Estradiol 1 mg, and Norethindrone Acetate 0.5 mg tablets by Sun Pharmaceutical Industries Limited.
The proposal was reviewed during the SEC (Reproductive) meeting held on 19th June 2025 at CDSCO Headquarters, New Delhi. The firm presented its Phase III clinical trial report, as per the committee’s earlier recommendation dated 20th March 2024.
This three-drug oral combination is designed to treat hormone-dependent gynecological conditions such as uterine fibroids and endometriosis, where suppression of estrogen plays a key therapeutic role. Relugolix, a non-peptide oral GnRH receptor antagonist, reduces secretion of LH and FSH from the pituitary gland, thereby suppressing ovarian hormone production and alleviating symptoms linked to estrogen-sensitive disorders.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.